MACH7 TECHNOLOGIES LIMITED — Capital/Financing Update 2025

Dec 2, 2025

ASX Announcement

3 December 2025

==> picture [104 x 26] intentionally omitted <==

MACH7 SIGNS NEW LOGO WITH UNITYPOINT HEALTH

• UnityPoint Health signs 5-year subscription licence for Flamingo Architecture product.

• Year 1 ARR[1] contribution of ~A$0.6M based on 1.5M studies per annum.

• ARR contribution expected to increase to ~A$1.0M ARR with projected growth in annual volumes to 3M studies during 5-year period.

• New contract effective from 3 December 2025 with FPU[1] expected within 12 months.

Mach7 Technologies Limited (“ M7T” or “the Company” ) (ASX:M7T) today announces it has signed a 5-year subscription licence agreement with first time customer UnityPoint Health for its new Flamingo Architecture products including its communication workflow engine and archive cache.

UnityPoint Health is an integrated not-for-profit health system based in Iowa, western Illinois and southern Wisconsin that serves almost eight million patients in hospitals, clinics and home health settings.

Following FPU, the five-year subscription licence will initially contribute approximately A$0.6 million to ARR, growing to approximately A$1 million. This is based on an increase in usage from a minimum of 1.5 million studies per year to an anticipated 3 million studies per year over the five-year term.

Mach7 CEO and Managing Director Teri Thomas said: “We are delighted to welcome UnityPoint Health to the Mach7 family. This agreement is not for our VNA nor our eUnity Viewer; instead, it represents the first commercial deployment of our new Flamingo Architecture, a modular offering positioned between the VNA and the eUnity viewer.

“UnityPoint is licensing specific components of Flamingo: our communication engine and archive cache, demonstrating the flexibility of this new architecture and underscoring Mach7’s strength in delivering speed, scale, and data independence across complex imaging workflows. With the recent reset of our sales organisation and marketing strategy, this agreement signals new momentum that we expect to further build through our active engagements with prospective customers at RSNA.”

Released on authority of the Board by Teri Thomas, Managing Director and Chief Executive Officer.

For more information, contact: Investor Relations

Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com

1 Year 1 Annual Recurring Revenue (ARR) follows go-live or First Productive Use (FPU).

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 T: 03 9692 7222 www.mach7t.com

ASX Announcement

==> picture [104 x 26] intentionally omitted <==

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, delivering advanced data management and diagnostic viewing solutions to healthcare organisations worldwide. The Mach7 Enterprise Imaging Solution (EIS) is a next-generation solution combining a powerful Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and robust diagnostic workflow applications. Built for maximum flexibility and scalability, Mach7 empowers customers to implement a complete enterprise imaging ecosystem or deploy modular components that fit their unique needs. Today, Mach7 supports a diverse global network, from large integrated delivery networks (IDNs) and national health systems to independent provider groups and private radiology practices. Visit Mach7t.com for more information.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company’s financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company’s management as well as assumptions made by, and information currently available to, the Company’s management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.

Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192 Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 T: 03 9692 7222 www.mach7t.com